Pediatric Dermatology

FDA will review a supplemental New Drug Application for topical roflumilast to treat infant AD with supporting trial data showing rapid itch relief and clear skin gains from week 1.

The episode highlights how clinicians integrate new therapies through mentorship, peer discussion, and real-world clinical experience.

FDA will review LEO Pharma's delgocitinib cream for adolescent patients aged 12-17 with CHE, backed by phase 3 gains and addressing a major treatment gap.

The guidelines formalize a stepwise treatment approach ranging from emollients and topical steroids to systemic therapies.

Steven Daveluy, MD, discusses how this approval helps close a critical gap in care for adolescents living with HS.

Jeff Yu, MD, discusses important issues in screening and addressing pediatric contact dermatitis at the AAD Annual Meeting.

Levy reflected on the importance of mentorship, collaboration, and the evolving landscape of pediatric dermatology at the Society for Pediatric Dermatology Pre-AAD Meeting.

Swanson and Silverberg explain why tween skin care trends harm barriers, and how clinicians can simplify routines and spot allergens.

Positive phase 3 findings from ADorable-1 suggest lebrikizumab could expand biologic treatment options for younger patients with atopic dermatitis (AD).

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

A new study reveals gaps in acne management for teens with PCOS; Hispanic patients are less likely to receive spironolactone, COCs, or isotretinoin treatment.

A survey of dermatology residents found that interest in subspecialty fellowships often declines during training, with financial concerns particularly affecting pediatric dermatology.

The reimagined Don’t Be Rash podcast positions industry leaders at the center of pediatric skin conversations.

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

Targeting IL-4 and IL-13 signaling with dupilumab has demonstrated significant reductions in total and food-specific IgE in pediatric AD populations.

Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

An educational smartphone app significantly reduced atopic dermatitis relapse in children, enhancing caregiver engagement and timely intervention.

Pediatric atopic dermatitis often leads to allergic comorbidities, increasing treatment needs and health care costs, according to a new Japanese study.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

A mother shares her personal journey with her daughter's chronic spontaneous urticaria, highlighting the emotional and treatment challenges faced by families.

Arcutis is advancing pediatric dermatology with innovative, steroid-sparing treatments for atopic dermatitis and plaque psoriasis, enhancing care for young patients.

At Elevate-Derm Fall, Ken Korber, PA-C, MHPE, DFAAPA, highlighted how literacy-aware communication and team-based collaboration can elevate patient understanding, adherence, and outcomes.

A Prescription Drug User Fee Act target action date is set for June 29, 2026.